Details of a Researcher - Furugen, Ayako

Furugen, Ayako

写真a

Affiliation: Faculty of Pharmacy, Department of Pharmacy ( Shiba-Kyoritsu )

Position: Associate Professor (Non-tenured)

Page Top ▲

Career 【 Display / hide 】

2013.04

-

2015.06

Hokkaido University, Hokkaido University Hospital
2015.07

-

2023.03

Hokkaido University, Faculty of Pharmaceutical Sciences
2024.04

-

Present

Keio University, Faculty of Pharmacy, Associate Professor
2024.05

-

Present

北海道大学, 大学院薬学研究院, 招へい教員（客員准教授）

Page Top ▲

Academic Background 【 Display / hide 】

2004.04

-

2008.03

Hokkaido University, Faculty of Pharmaceutical Sciences, 総合薬学科

University, Graduated
2008.04

-

2010.03

Hokkaido University, Graduate School of Life Science, 生命医薬科学コース　修士課程

Graduate School, Completed, Master's course
2010.04

-

2013.03

Hokkaido University, Graduate School of Life Science, 生命医薬科学コース　博士課程

Graduate School, Completed, Doctoral course

Page Top ▲

Licenses and Qualifications 【 Display / hide 】

薬剤師免許, 2008.04

Page Top ▲

Research Areas 【 Display / hide 】

Life Science / Clinical pharmacy

Page Top ▲

Papers 【 Display / hide 】

Evaluation of intestinal absorption of deoxyribonucleic acid components in salmon milt extract using in-situ and in vitro gastrointestinal absorption models.

Taguchi R, Narumi K, Ueda H, Satoh H, Mori T, Okamoto K, Furugen A, Kobayashi M.

2026.01

Research paper (scientific journal), Joint Work, Accepted
Placental transfer of third-generation antiepileptic drugs: in vivo lacosamide case study and in vitro investigation of transporter inhibition by lacosamide and perampanel.

Ueda A, Furugen A, Nishimura A, Umazume T, Aoyagi R, Okamoto K, Narumi K, Ueda H, Kobayashi M.

J Pharm Health Care Sci. 2026.01

Research paper (scientific journal), Joint Work, Corresponding author, Accepted
- Access to Document (DOI)
Validity and Utility of a Risk Prediction Model for Wound Infection After Lower Third Molar Surgery

Akira Yamagami, Katsuya Narumi, Yoshitaka Saito, Ayako Furugen, Shungo Imai, Keisuke Okamoto, Yoshimasa Kitagawa, Yoichi Ohiro, Ryo Takagi, Yoh Takekuma, Mitsuru Sugawara, Masaki Kobayashi

Oral Diseases (Wiley) 31 ( 6 ) 1922 - 1931 2025.06

Research paper (scientific journal), Accepted, ISSN 1354523X

　View Summary

ABSTRACT

Objectives

To externally validate a clinical prediction model for surgical site infection (SSI) after lower third molar (L3M) surgery and evaluate its clinical usefulness.

Methods

We conducted a retrospective cohort study of patients who underwent L3M surgery at Hokkaido University Hospital. The study was designed to evaluate the historical and methodological transportability. Clinical usefulness was evaluated using decision curve analysis on the data of the non‐antibiotic‐treated patients.

Results

We obtained 2543 validation cohorts from April 2020 to March 2023, and 640 non‐antibiotic cohorts from July 2010 to September 2023. The incidences of SSI after L3M surgery were 5.3% (135/2543) and 7.7% (49/640) in the validation and non‐antibiotic cohorts, respectively. The discrimination ability of the prediction model was acceptable for the external validation cohort (c‐statistic: 0.67; 95% CI: 0.62–0.71) and adequate for the non‐antibiotic cohort (c‐statistic: 0.72; 95% CI: 0.63–0.79). In both cohorts, the model showed excellent calibration between the observed and predicted probabilities. Decision curve analysis showed increased net benefit across a range of meaningful risk thresholds.

Conclusion

A simple risk prediction model for SSI after L3M surgery demonstrated clinical transportability and usefulness. This model may help surgeons/clinicians determine the appropriateness of prophylactic antibiotics administration for patients in L3M surgery.
- Access to Document (DOI)
Analysis of drug transporter expression in syncytiotrophoblast derived from human placental stem cells: Expression and function of efflux transporters.

Riko Sawada, Ayako Furugen, Ayami Ueda, Ayako Nishimura, Takeshi Umazume, Katsuya Narumi, Masaki Kobayashi

Placenta 165 23 - 32 2025.05

Research paper (scientific journal), Corresponding author, Accepted, ISSN 01434004

　View Summary

OBJECTIVE: The placenta is a vital organ for exchanging nutrients, endogenous substances, and xenobiotics between mother and fetus. The syncytiotrophoblast (ST) is crucial in maintaining the placental barrier. Human trophoblast stem cells (hTSCs) have been recently established; however, their utility in studying placental transport functions has not been fully elucidated. This study investigated the expression and function of transporters in hTSC-derived ST cells. METHODS: TSCT cells, as hTSCs, were differentiated into ST-like cells (ST-TSCT), and the gene expression of 84 transporters in ST-TSCT cells was evaluated using a PCR array. BeWo cells, a widely used trophoblast model, were used for comparison. BeWo cells were differentiated into ST-like cells using forskolin [BeWo (FK)]. The protein levels of efflux transporters were examined by western blotting, and functional assays were performed using typical fluorescent substrates. RESULTS: Transporter gene expression levels were higher in ST-TSCT than in BeWo (FK) cells, with 27 genes showing more than a 3-fold increase. Ten of these genes were exclusively expressed in ST-TSCT. Western blotting revealed the presence of efflux transporters, including P-glycoprotein (P-gp/ABCB1), breast cancer resistance protein (BCRP/ABCG2), and multidrug resistance-associated protein 2 (MRP2/ABCC2). Furthermore, the accumulation of typical substrates (Rhodamine123 for P-gp, Hoechst33342 and BODIPY™ FL Prazosin for BCRP, and 5(6)-carboxy-2',7'-dichlorofluorescein diacetate for MRP) significantly increased when transporter inhibitors (elacridar, Ko143, and MK571) were applied. CONCLUSION: This study showed higher transporter expression in ST-TSCT than that in a traditional trophoblast model. Furthermore, the functional expression of efflux transporters was observed. ST-TSCT is valuable for investigating placental transport functions.
- Access to Document (DOI)
Evaluation of the Effect of Aldehyde Oxidase Inhibitors on 6-Mercaptopurine Metabolism

Ueda H., Narumi K., Furugen A., Okamoto K., Saito Y., Kobayashi M.

Biological and Pharmaceutical Bulletin 48 ( 5 ) 713 - 720 2025.05

Research paper (scientific journal), Accepted, ISSN 09186158

　View Summary

Thiopurines, such as 6-mercaptopurine (6-MP) and azathioprine, are converted to the inactive metabolites 6-thioxanthin (6-TX) and 6-thiouric acid (6-TUA). Molybdenum-containing oxidoreductases, aldehyde oxidase (AOX) and xanthine oxidase (XO), are involved in the oxidation of 6-MP to 6-TX; XO inhibitors affect the therapeutic efficacy of thiopurines and the incidence of adverse effects, such as liver and blood disorders. However, the role of AOX in the pharmacokinetics of 6-MP remains unclear. To clarify the clinical importance of AOX-mediated drug–drug interactions, we evaluated whether drugs that inhibit AOX affect 6-MP metabolism. The metabolism of 6-MP to 6-TX was strongly inhibited by AOX inhibitors (amitriptyline, chlorpromazine, clomipramine, clozapine, hydralazine, quetiapine, and raloxifene) in a reaction mixture containing human liver cytosol. The inhibition of 6-TX production rate by each AOX inhibitor was 60–70% at high concentrations, although the XO inhibitor febuxostat showed an inhibition rate of 10–30%. Furthermore, the combination of febuxostat and each AOX inhibitor showed greater inhibition than when each compound was added alone. The AOX inhibitor did not alter 6-MP oxidation by recombinant XO. These results suggest that AOX inhibition may affect the pharmacokinetics of thiopurines. However, because of the lower activity of AOX in rats than that in humans, the contribution of AOX could not be assessed using in vivo experiments. Further studies are needed to evaluate the contribution of AOX to the therapeutic and adverse effects of thiopurines, both in clinical studies and in animal models of liver humanization.
- Access to Document (DOI)

display all >>

Page Top ▲

Reviews, Commentaries, etc. 【 Display / hide 】

Reply to Accurate Risk Prediction Model for Surgical Site Infection After Lower Third Molar Surgery.

Akira Yamagami, Katsuya Narumi, Yoshitaka Saito, Ayako Furugen, Shungo Imai, Yoshimasa Kitagawa, Yoichi Ohiro, Ryo Takagi, Yoh Takekuma, Mitsuru Sugawara, Masaki Kobayashi

Oral diseases 31 ( 4 ) 1374 - 1375 2025.04

ISSN 1354523X
- Access to Document (DOI)
オレキシン受容体拮抗薬のUPLC/MS/MS定量法構築とヒト乳汁移行性評価への応用

石川陽菜, 古堅, 彩子, 西村, あや子, 馬詰, 武, 青柳, 亮一, 石川, 修平, 鳴海, 克哉, 岡本, 敬介, 武隈, 洋, 菅原, 満, 小林正紀

日本TDM学会 2024.07
Functional analysis of hMCT2 involved in memory formation and the exploration of its high selective inhibitors

山口敦史, 山口敦史, 向井悠斗, 佐久間智也, 岡本敬介, 古堅彩子, 鳴海克哉, 小林正紀

日本薬学会年会要旨集(Web) 144th 2024

ISSN 0918-9823
AOX1遺伝子の5’上流および3’非翻訳領域におけるSNP解析

林愛, 鳴海克哉, 上田一奈太, 岡本敬介, 古堅彩子, 小林正紀

TDM研究 41 ( 2 ) 2024

ISSN 0911-1026
メトトレキサート誘発性肝障害におけるアルデヒドオキシダーゼの寄与-基礎および薬剤疫学的アプローチによる検証-

鳴海克哉, 森山綾子, 上田一奈太, 淺野秀峰, 古堅彩子, 小林正紀

医療薬学フォーラム講演要旨集 31st 2023

ISSN 1348-0863

display all >>

Page Top ▲

Research Projects of Competitive Funds, etc. 【 Display / hide 】

母体痩せによる糖代謝物の母体-胎児間の動態変化と子への影響

2024.08

-

2025.08

一般財団法人糧食研究会, 令和6年度（2024年）一般公募研究, Principal investigator
周産期の安全な精神神経科系薬剤の服薬支援のためのエビデンス構築

2024.04

-

2027.03

日本学術振興会, 科学研究費助成事業, 基盤研究(B), No Setting
トロホブラスト分化マーカーを指標とした薬剤による胎児毒性の新規評価法の開発

2023.11

-

2024.06

横山臨床薬理研究助成基金, 令和5年度研究助成（一般研究助成）, Principal investigator
胎盤幹細胞由来syncytiotrophoblastを用いた薬物の胎盤通過性評価とメカニズムの解明

2023.08

-

2025.03

日本学術振興会, 科学研究費助成事業, 研究活動スタート支援, No Setting
女性におけるVitamin D 状態の評価と胎盤機能との関連性

2022.07

-

2023.06

公益財団法人三島海雲記念財団 2022年度学術研究奨励金, Principal investigator